As the founding CEO of FDNA, Dekel Gelbman leads the corporate and business strategy of an innovative digital health company that develops technologies and SaaS platforms used by thousands of clinical, research and lab sites globally in the clinical genomics space. Using the most advanced deep learning and artificial intelligence technologies, FDNA has created a new gold standard - next-generation phenotyping (NGP) - technologies that capture, structure, and analyze complex human physiological data to produce actionable genomic insights from next-generation sequencing data. Since its founding in 2011, FDNA has positioned itself at the forefront of AI, genomics and precision medicine, and is one of the most active and innovative startup companies in this space. Before joining FDNA, Mr. Gelbman was a practicing corporate and transactional attorney working for leading law firms, including among others, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates. Mr. Gelbman's experience includes working closely with a variety of technology and biotech companies, at all stages - from startups through growth stage companies and to mature, publicly-traded companies. Mr. Gelbman holds an LL.B and an MBA in finance.